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Undernutrition (malnutrition) is both a risk factor for and consequence of active TB disease. 
Wasting and malnutrition are common clinical findings in patients with active TB disease and 
are associated with mortality, but the mechanism/s of effect are not well understood and there 
is a lack of high quality evidence to determine the efficacy of interventions to prevent or treat 
malnutrition in TB patients, in the Philippines or globally.    
Diabetes mellitus is another known risk factor for active TB disease and has been associated 
with risk of death and poor treatment outcomes whilst TB may also negatively affect glycaemic 
control. Under-diagnosis or poor management of diabetes may increase of poor TB treatment 
outcomes. Co-morbid diabetes may also contribute to an increased financial burden and 
potentially catastrophic levels of costs. 
The aim of this study is to quantify the effects of malnutrition and diabetes in both drug-
resistant TB (DR-TB) and drug sensitive2 (DS-TB) patients  attending  public facility TB 
DOTS programmes in the Philippines on TB treatment outcomes. The overall goal is to  inform 
future operational research on optimal screening and management of diabetes in TB DOTS 
clinics in the context of TB populations who may be experiencing both under and over-
nutrition; and, to assess the need for and potential trial design of nutrition support interventions 
to improve TB treatment outcomes. 
1.2. Objectives 
The primary objective is to estimate the effect of malnutrition and diabetes on risk of adverse 
treatment outcome (death, loss to follow-up, default or treatment failure) in DR-TB patients 
enrolled on the WHO shorter (Bangladesh) regimen and DS TB patients attending TB-DOTs 
outpatient facilities. A secondary outcome definition will include relapse/recurrent active TB 
disease within 2 years of completing treatment in the definition of “adverse treatment outcome”  
 
1.3. Methods 
Study Design: Prospective cohort study 
Population and sample size: 800 TB outpatients attending public facility TB-DOTS clinics in 
Metro Manila, Negros Occidental and Cebu, including a target of 300 DR-TB patients.  
Eligibility: All consenting pulmonary TB patients ≥18 years newly initiating TB treatment from 
selected TB DOTS clinics including DR-TB, if enrolled on the WHO shorter treatment regimen 
but excluding pregnant women. 
Duration: Recruitment is expected to take 12 months, from April 2018 to March 2019. Follow-
up will be until 24 months post-treatment completion.  
Primary outcome measures: Adverse TB treatment outcome defined as death, loss to follow-
up, default or treatment failure at the end of treatment completion..  
Primary exposures: Malnutrition (BMI <17.0 kg/m2) and diabetes (random plasma glucose 
(RPG)≥11.1mmol/L (200mg/dL) confirmed by HbA1c≥6.5%, or previous diagnosis and on 




                                               
2 DS-TB defined as TB patients enrolled on category I or II  ATT regimens who may or may not have had 
GeneXpert testing to determine rifampicin resistance 
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2. Background and justification 
 
2.1. Malnutrition and Tuberculosis.  
Tuberculosis and malnutrition are known to be closely associated with each other with even 
mild malnutrition increasing the risk of developing active TB disease [1]; TB can directly 
contribute to the development of malnutrition by increasing metabolic demands and inducing 
a catabolic state and decreased appetite and potentially through indirect effects on access to 
nutritious food through effects on poverty and isolation. Malnutrition in TB has been associated 
with risk of death in TB patients. Kwon et al reported an odds ratio (OR) of 2.8 (95%CI 1.59 
– 4.93) for mortality in a Korean cohort of TB patients with a BMI <18.5 kg/m2 [2]. Whilst in 
an Indian cohort of 1,523 newly diagnosed TB out-patients, Bhargava et al reported a 22% 
decreased odds of mortality risk per unit increase in BMI at time of diagnosis (adjusted OR 
0.78; 95%CI 0.68-0.90) [3]. Although the evidence for the association between malnutrition 
and risk of death in active TB is reproducible, there is insufficient information to try to 
determine causality. In a study of 1181 TB patients in Malawi, despite an odds ratio of 1.8 
(95%CI 1.1 – 2.7) for death within the first 4 weeks of treatment in those with moderate/severe 
malnutrition, the authors concluded that severity of disease or comorbidities such as HIV may 
confound this finding [4]. Whether interventions to treat protein-energy malnutrition in TB can 
improve TB-related outcomes is not known.  Only 7 trials of macro-nutrient interventions in 
patients with active TB disease were included in a recent 2016 Cochrane review [5] and WHO 
policy document [6] and none were adequately powered to assess TB treatment outcomes. Both 
reports concluded that there is an urgent need for high-quality trial evidence to inform 
guidance. Furthermore, population specific evidence is required and within the context of 
recent improvements in diagnosis and treatment of TB. 
 
2.2. Tuberculosis and Malnutrition in the Philippines.  
As of the Global Tuberculosis Report 2017, the Philippines is ranked 4th in the world for total 
TB burden with an estimated incidence of 554 per 100,000 population [7] including the 
estimated incidence of HIV-TB co-infections of 5.9/100,000 population. The estimated DR 
incidence rate is 30 per 100,000 population. Estimated mortality rates in HIV-negative TB 
cases is 21 per 100,000 [7]. There is little published data on nutritional status of TB patients in 
the Philippines. However, to our knowledge, the best and most recent available data on 
malnutrition and diabetes in Filipino TB patients is from our recently completed cross-sectional 
study of patients registered at 5 outpatient TB-DOTS clinics (ISRCTN12506117) in Metro 
Manila and Negros Occidental in which 90% of patients were on category 1 or 2 treatment 
regimens. The overall prevalence of moderate and severe malnutrition (BMI<17) was 20.5%  
(Table 1). and when including mild malnutrition (BMI<18.5)  50%. In contrast, around 10% 
of the general adult population have a BMI<18.5 [8]. Moderate and severe malnutrition rates 
are higher within 1 month of treatment than at 5 months or more of treatment (26% vs 17%) 
(Table 2).   This shows that malnutrition persists above the expected adult malnutrition rates 
(10%) even after TB treatment, suggesting that treatment of TB alone may not be enough to 
resolve malnutrition. What is not known is if apparently increased rate of malnutrition at the 
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end of treatment is due to to the socio-economic effects of TB, likely to affect all household 
members or due to inherent effect of TB disease.  The proportion of TB-DOTS patients 
determined to be food insecure using the Adapted U.S. Household Food Security Survey 
Module was 62% in the more rural clinics in Negros Occidental compared to 36% in Metro 
Manila.  In a prospective cohort of Filipino patients with MDR-TB, weight gain in patients 
who were underweight before treatment was significantly associated with decreased risk of 
adverse treatment outcome including death, default or treatment failure [9].  Factors identified 
with  a reduced risk of  default from treatment in Filipino MDR-TB patients included food 
provision, travel reimbursement and free provision of drugs for managing nausea/vomiting side 
effects of the drugs through TB programmes [10] supported by analysis of patient views of 
barriers to treatment adherence in which 60% of patients included the importance of food 
provision [11].  
 
Table 1. Prevalence of moderate and severe malnutrition and diabetes in TB-DOTs 
outpatients 
  Moderate & severe 
malnutrition [BMI<17.0kg/m2] 
Diabetes* 
Manila (total) 16.7% (56/336) 8.6% (28/324) 
Negros Occ. (total) 24.8% (74/298) 11.7% (31/264) 
Total of all sites 20.5% (130/634) 10.0% (59/588) 
*previously diagnosed or HbA1c > 6.5% 
  
Table 2. Prevalence of moderate and severe malnutrition and anaemia by duration of 
treatment in TB-DOTS outpatients 
  Months of treatment Total 
  <1month 1-2months 3-4 months 5+ months   
BMI<17.0kg/m2 25.8% (51/198) 20.8% (33/159) 16.5% (22/133) 16.7% (24/144) 20.5% (130/634) 
Mod or Severe anaemia* 20.2% (40/198) 15.1% (24/159) 9.1% (12/132) 7.0% (10/143) 13.6% (86/632) 
*Moderate/severe anaemia = Hb< 11.0g/dl for both sexes. 
 
2.3. Tuberculosis and Diabetes Mellitus. 
The burden of diabetes mellitus (DM) has been increasing worldwide. The link between 
diabetes and TB has long been known since Richard Morton’s treatise of Consumptions in 
1694. However, the effect of diabetes on immune function dysregulation and its role in 
increased risk of TB is still not well characterized [12, 13]. A meta-analysis of cohort studies, 
with most data coming from a single study in South Korea, suggests an age-adjusted RR for 
risk of active TB of 3.11 [95% CI 2.27-4.26] [14], which is likely to be higher in high 
transmission settings. It has been estimated that 15% of 10.4 million newly diagnosed adult TB 
cases may be attributable to diabetes [15]. The risk of MDR-TB also appears to be increased 
by diabetes, as reported in a recent meta-analysis (OR=1.71 [95% CI 1.32 -2.22]) [16]. 
Diabetes, has also been associated with an in increased risk of poor treatment outcomes in a 
meta-analysis of mostly retrospective studies [17] and poor glycaemic control in a relatively 
large prospective study in South Korea [18], including significant effects for risk culture 
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positivity at 2 months, treatment failure and death, even after adjustment for important 
confounders. However, many studies so far are from high-income settings, are retrospective, 
or rely on clinical records or sub-optimal diabetes testing or have not adequately addressed 
potential sources of bias and confounding and thus various methodological issues remain, thus 
leading to uncertainty over these estimates of effect [19]. The effects of diabetes are also likely 
to be heavily context dependent and thus further epidemiological research of the effect of 
diabetes on TB treatment outcomes is urgently called for [20].  
2.3.1. Tuberculosis and Diabetes Mellitus in the Philippines.  
Type 2 DM is increasing in prevalence in the Philippines. The prevalence of elevated fasting 
blood sugar (FBS) among Filipino adults based on the National Nutrition and Health Survey 
(NNHeS) was 5.6% in 2013 [8]. However, a more accurate prevalence of diabetes in a national 
survey in 2008 which included previous diagnosis by a health practitioner and FBS plus the 
oral glucose tolerance test (OGTT) reported a prevalence of 7.2% [21]. Thus, at the present 
time the prevalence of diabetes is probably closer to 8% and it is expected that DM-associated 
TB cases will also increase [22]. In a recent rapid situational analysis in the Philippines the 
limited data of DM in TB was highlighted as a barrier to planning a coordinated response [22]. 
In our recently completed cross-sectional study in TB-DOTs outpatients, the overall prevalence 
of diabetes was 10%, with 12.5% in the more rural clinics and 8.6% in Manila (Table 1), of 
whom 65% and 52% were previously undiagnosed.  Around half of those who with a previous 
diabetes diagnosis had poor glycemic control.  
 
2.4. Malnutrition, diabetes and immune responses to TB 
The observed association between malnutrition and risk of active TB disease is probably due 
to malnutrition associated depression of cell-mediated immunity leading to increased risk of 
infection and/or progression to active disease, although a lot of the available evidence is from 
animal models with very little data on immune functions linked to good nutritional, clinical 
and epidemiological data [23]. Additionally, despite recent progress, the immune response to 
TB remains relatively poorly understood [24] and we do not understand the role of the immune 
response in determining response to treatment. Diabetes may increase the risk of TB infection, 
active TB disease and adverse treatment outcomes through altered glucose metabolism, and 
increased inflammation and oxidative stress antigen presenting cells and the balance Treg, Th1-
, Th2- mediated responses and neutrophil and phagocyte capacity to kill infected cells [12]. 
Interferon-gamma release assays measure IFN-γ produced by T-cells in response to TB specific 
antigens either by counting cells producing IFN-γ (T-SPOT) or the amount of IFN-γ in the 
supernatant after whole blood stimulation with M.tb antigens distinct from those used in BCG 
vaccination (e.g. QuantiFERON-Gold). In addition, the new version, QuantiFERON-Gold-
Plus, uses separate antigens that stimulate CD4+ and CD8+ cell dominated responses. These 
standardised kits are designed to test for the presence of TB infection as determined by a IFN-
γ response over s standardised cut-off, which in the absence of clinical disease is interpreted as 
indicating latent TB-infection. However, ex-vivo stimulation of blood using these standardised 
kits also provides the opportunity to interrogate immune responses in more detail including 
assessment of patterns of multiple cytokine responses, which are being investigated as potential 
7 
St-ATT V2.0 3rd May 2019 
 
biomarkers of response to treatment [25] and of development of active TB disease [26]. 
However, currently most of this work is being developed using populations from either high-
income countries or not accounting for potential variation that is likely to be occurring from 
co-morbid malnutrition and diabetes in the kinds of patients in which such tests are intended 
for eventual use.  
 
2.5. Tuberculosis Patient costs.  
TB is a cause and consequence of poverty [27] potentially trapping patients and their 
households in a cycle of poverty. Healthcare financing in low-income countries is characterized 
by out-of-pocket expenditures and a lack of financing mechanisms and weak health insurance 
structures. If total costs due to TB are greater than 20% of household annual income, the 
situation may be considered catastrophic as the threshold was most strongly associated with 
adverse TB outcome [28, 29]  
One of the pillars of the WHO End TB strategy is “to ensure that no family is burdened with 
catastrophic expenses due to TB” [30]. To capture the current situation of TB associated 
household costs and monitor the progress to achieve this goal, WHO promotes countries with 
a high a TB burden to conduct baseline and periodic TB patient cost surveys [29]. The current 
guideline is to conduct TB patient cost study using a cross-sectional design for simplicity and 
practicality. In the Philippines, the Filipino NTP conducted a nationwide TB patient cost study 
collaborating with WHO in 2015–2016 and the study assessed direct costs (e.g. costs for TB 
drugs, consultations, hospitalization, or transportation, or special foods) and indirect costs (e.g. 
opportunity costs due to time loss to visit and in health facilities, loss of job or unwell to work). 
The results of the study found a large contribution of “nutritional supplements” and 
“opportunity costs” to patient catastrophic costs (20% total cost, oral presentation at PhilCAT 
2017). However, this study, and all others completed so far [29] have been cross-sectional and 
have not assessed costs of diabetes diagnosis and treatment in TB patients. 
We have already piloted a version of the WHO TB patient cost tool, which we adapted to 
include additional specific questions on direct and indirect costs of diabetes diagnosis and 
treatment using the same format as used for TB and which we deployed electronically using 
Open Data Kit (ODK). Our preliminary results from this pilot in 47 DS patients, 21 in intensive 
& 26 in the continuation phase of treatment and 4 with co-morbid diabetes found that 
expenditure on nutritional supplements was twice that of drugs and diagnostic tests and that 
income losses accounted for >70% of total patient incurred costs.   
The Filipino Department of Health introduced a policy for bi-directional screening of TB and 
DM in 2017, as proposed by the current End TB strategy. However, this policy has not been 
fully implemented in TB programmes and there is little data or research on which to assess 
operational feasibility and likely benefits of doing so, including in the potential for reducing 
patient costs by integration of diabetes services within TB programmes. No data are yet 
available from other countries on implementation of or cost effectiveness of integration of 
services or bi-directional screening. As costs for diabetes diagnosis & management are not 
always fully covered by national insurance or Philippines government [31, 32], though direct 
costs for TB treatment and diagnosis are covered, this may result in increased and potentially 
catastrophic costs in patients with TB and co-morbid diabetes and increased needs for social 
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protection mechanisms. Similarly, if co-morbid malnutrition is not being diagnosed and 
managed by health facility staff, patients may be spending money on potentially inappropriate 
supplements in an effort to self-manage.  
 
2.6. Adherence  
Risk factors which may affect TB treatment adherence include duration of treatment, 
combination of several therapies, unpleasant side effects, high patient costs and burden, stigma, 
depression, lack of social and family support, traditional health beliefs, poor communication 
between health care providers and patients, and lack of disclosure of diseases status [33]. DM 
may also affect TB adherence due to increased burden of multiple therapies (costs and time), 
drug-drug interactions and effects of DM on lifestyle disruption and quality of life and 
metabolic effects [33, 34]. Malnutrition can increase non-adherence due to poor appetite, 
metabolic changes  and associations with quality of life [35]. MDR-TB is associated with lower 
health-related quality of life (HRQOL) than DS-TB [37]. However, the association between 
adherence to treatment and HRQOL has rarely been studied in TB [38], and pathways leading  
to be non-adherent are not well described. 
The main reasons for non-adherence in MDR-TB are usually stated to be the increased number 
of medications and long duration of TB treatment [40]. The normal MDR treatment duration 
is 18 months while NTP has introduced the WHO shorter regimen with a duration from 9 to 12 
months [41]. This shorter regimen is expected to improve adherence level due to reduced 
patient burden from duration of treatment and reduced time burden for receiving treatment by 
change the treatment place from PMDT facilities (which usually have a far distance to be 
reached) to DOTS [41]. There are no available data or publication assessing the effect of 
diabetes and malnutrition on TB treatment adherence in the Philippines. Also, information on 
risk factors associated with non-adherence and of the pathways to be non-adherent are not well 
known in the Philippines, or elsewhere.  
2.7.   Long-term Health outcomes and social effects of TB treatment   
Although TB is recognized as a globally important cause of mortality, TB associated morbidity 
after treatment and long-term health effects are not well documented. Limited recent data from 
diverse populations suggest that TB patients, including those who are who are 
microbiologically cured, may suffer from significant long-term lung damage as defined by 
imaging [33] or pulmonary function impairment assessed using spirometry; [34-38] whilst few 
studies have attempted to relate physiological impairment with quality of life and other 
important health related outcomes. Recurrent TB, older age and HIV are documented risk 
factors for post-treatment decreased lung function, but the effects of malnutrition and diabetes 
are not known, although some studies have reported increased radiological severity in TB-DM 
patients, particularly those with poor glycaemic control [39], and in those with more severe 
malnutrition [40]. Patients with long-term lung damage/decreased function are also likely to 
experience increased risk of developing further lung diseases such as severe pneumonia and 
obstructive lung diseases such as COPD and bronchiectasis, conditions which already pose a 
major burden on health expenditure and morbidity in the Philippines.  
Previous data from our cross-sectional study in Filipino TB patients indicated 16.5% of patients 
in the final months of treatment to still have moderate or acute malnutrition and 7% moderate 
or severe anaemia (Table 2). It is not known how these conditions may evolve post-treatment 
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or of their effects on productivity (e.g. ability to work) and quality of life. Furthermore, the 
effects of TB at the level of the household are not well documented or of the long-term effects 
of TB-associated costs.   
Although treatable, TB patients face discrimination from the community as well as self-
discrimination post-treatment which may continue to affect individuals psychosocial/mental 
health even after successful treatment.  
There is one currently ongoing multicountry study in 4 African countries that is seeking to 
systematically assess the long term medical and social sequale of TB;  the TB Sequel study 
[41]. We propose to maximise the use of our large treatment cohort to address these questions 
in an Asian population using similar methodologies.   
3. Study aims and objectives  
3.1. Aim 
The aim of this study is to measure the effects of malnutrition and diabetes in patients with 
tuberculosis and investigate associations with treatment outcome through potential effects on 
treatment compliance, drug side effects, glycemic control, weight gain and nutrition during 
treatment and cell-mediated immune responses. 
3.2. Primary Objective 
The primary objective is to estimate the effect of malnutrition (BMI<17.0 kg/m2) and diabetes 
on risk of adverse treatment outcome (death, loss to follow-up, incomplete treatment or 
treatment failure) in in DS-TB patients3  and DR-TB patients enrolled on the WHO shorter 
(Bangladesh) regimen. A secondary outcome definition will also be analysed including 
relapse/recurrent active TB disease within 2 years of completing treatment in the definition of 
“adverse treatment outcome”  
3.3. Secondary Objectives 
1. To investigate the effect of malnutrition, diabetes and pre-diabetes at enrolment on time 
taken for patients to be negative for M.tb bacteria by standard programmatic tests (direct 
sputum slide microscopy, (sputum culture for DR-TB) as available.   
2. To describe management of diabetes in TB patients and glucose control as assessed by 3-
monthly HbA1c.   
3. To investigate the stability and basis of glucose dysregulation and diabetes during and after 
TB patient treatment. 
4. To determine if malnutrition (BMI <17.0 kg/m2) and HbA1c, diabetes and pre-diabetes 
affect cell mediated (CD4 and CD8) immune responses to TB-specific antigens in whole 
blood samples stimulated with Quantiferon TB Gold-Plus.  
5. To estimate total patient costs in patients with DS-TB and DR-TB receiving the shorter 
regimen and investigate the effect of costs associated with co-morbid malnutrition and 
diabetes on the percentage of patients with catastrophic costs over the duration of treatment 
(using adapted WHO costing tool). 
                                               
3 DS-TB defined as TB patients enrolled on category I or II  ATT regimens who may or may not have had 
GeneXpert testing to determine rifampicin resistance 
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6. To determine if malnutrition and anaemia are more common in TB patients compared to 
household contacts without TB, who share socio-economic and other factors that may 
affect  nutritional status. 
7. To assess the effect of malnutrition and DM on TB treatment adherence and investigate 
potential pathways of effect including depression, stigma, social & family support (SFS), 
medication side effects and self-esteem. 
8. To document the long-term health and psychosocial sequalae in TB patients post-
treatment  including lung function, diabetes, malnutrition, quality of life, depression and 
anxiety, and risk of recurrent TB up to 2 years post-treatment and investigate their 
associated risk factors.   
3.4. Significance of the Study 
This study will estimate the effect of malnutrition and diabetes among TB patients on their 
treatment outcomes in a predominantly HIV-negative population. This sets the stage to 
determine the potential impact of targeted co-interventions to improve nutritional status or 
improve glycemic control.  Furthermore, the amended version to include post-treatment follow-
up will determine the previously undocumented long-term health sequalae of TB and their risk 
factors, adding further evidence of the need/type of interventions to improve TB-associated 
outcomes. Together with the clinical, immunologic and costing data, the study is well-
positioned to provide information that would directly contribute to future research and program 
direction.  
3.5. Research design 
This is a facility-based prospective cohort study in TB DOTs facilities in the Philippines.  
3.6. Study Population and Locale 
Study participants aged 18 or more (adults) who are initiating a new TB treatment regimen to 
be recruited from participating NTP DOTs and iDOTS centres (i.e. those implementing the 
WHO shorter regimen to eligible DR-TB patients) within the National Capital Region, Negros 
Occidental and Cebu. One adult household contact of enrolled TB-index cases will also be 
enrolled as a comparison group for malnutrition and anaemia.  
Current selected sites include: 
 
Manila, NCR 
- San Lazaro Hospital  
- San Nicholas H/C MHO 
Negros Occidental, Western Visayas  
- Valladolid H/C 
- Bago City H/C  
 
>>Updated [April 2019] active site list since study start as of April 2019.  
Negros Occidental, Western Visayas  
- Bacolod H/C 
- La Carlota H/C 
- Pablo O. Torres Memorial Hospital  
11 
St-ATT V2.0 3rd May 2019 
 
Cebu, Central Visayas  
- Compostela H/C 
- Carmen H/C 
- Consolacion H/C 
- Eversley Childs Sanitarium and General Hospital  
- Lapu Lapu City Health Office  
 
None of these sites are currently engaged in other TB or health related research projects, except 
for SLH, which has multiple research projects for inpatients, including a phase 2 of a TB 
inpatient study (PI Prof Cox) planned to start in the 2nd half of 2018. Other sites to be selected 
will include those who are not currently undertaking any research in the TB outpatients – to 
ensure that patient burden is minimised.  
 
3.7. Eligibility Criteria 
Subject Inclusion Criteria: Active TB cases 
● Patients initiating a new TB DOTS treatment regimen with bacteriologically confirmed 
or clinically diagnosed pulmonary TB , including: 
a. new diagnoses,  
b. relapse,  
c. treatment after failure,  
d. treatment after loss to follow-up (TALF),  
e. previous treatment unknown outcome (PTUO)  
● DR-TB cases (if initiating the 9-12 month WHO shorter DR-TB regime and registered 
to be managed at participating iDOTS clinic)  
● intending to reside within the study area for the duration of their treatment 
● Age ≥18 years old 
Subject Inclusion Criteria: Household contacts 
● Adult (Age ≥18 years old) household contact (defined as living in the same household 
for a minimum of 2 months before diagnosis of the index case) of active TB patients 
enrolled in the St-ATT cohort. 
● Screened and diagnosed as not having active TB (as available through programmatic 
screening). 
Subject Exclusion Criteria 
● Pregnant woman 
● Age <18 years old 
● Plan to move away from the study site or do not give consent to participate 
● Started the current ATT regimen more than 5 days before enrolment. 
● Currently imprisoned*4 
● Severe medical or psychiatric disorder which in the opinion of the local investigators 
might interfere with the ability to give true informed consent or to adhere to the study 
requirements* 
                                               
4 * Further exclusion criteria added since starting enrolment. 
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● Taking part in any investigational product trials related to TB and/or lung disease or 
diabetes.* 
 
3.8. Definitions of Outcomes and key exposures 
• The primary outcome of adverse treatment outcome will be defined as: death, loss to 
follow-up (default defined as  2 or more consecutive months of interrupted treatment), 
or treatment failure). A secondary outcome definition of adverse treatment outcomes 
will include recurrent TB diagnosed clinically or microbiologically as per the local 
procedures up to years after completing treatment.  
• Diabetes will be defined (random plasma glucose (RPG)≥11.1mmol/L (200mg/dL) 
confirmed by HbA1c≥6.5%, or previous diagnosis and on treatment) 
• Malnutrition will be defined using BMI  with moderate or severe malnutrition defined 
as BMI<17 kg/m2 used in the primary analysis.  
 
3.9. Recruitment  
Newly registered eligible patients at TB DOTs clinics will be recruited by research staff. The 
study will be explained to them, and if they agree, a written informed consent will be obtained 
(see 8.1 below). Once a registered patient is recruited, a separate consent to participate in the 
study will be obtained from eligible household contacts using the same consent process. A TB 
patient remains a participant even if the household contact refuses. 
  
3.10. Data Collection 
3.10.1. Sample collection and study assessments: 
All study participants will be seen by a study research nurse at enrolment and thereafter all 
participants will be seen at monthly follow-up at the registered TB-DOTS clinic or Barangay 
health station where receiving/collecting treatment until treatment completion depending on 
TB treatment regimen. Study assessments samples and data collected during treatment are 
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Table 3A: Summary of data & sample collection in participants during treatment 
Assessment Time points  0M Monthly 3M 6M 9M1 12M1 
Demographics, clinical history, household information ü      
TB & Diabetes Medication History, adherence; adverse effects  ü     
TB Classification, diagnosis, regimen ü      
Sputum Sample [sputum archived] ü      
Chest x-ray (if required2) ü      
Anthropometry [BMI, MUAC, waist:hip ratio]; grip strength, 
blood pressure, reported appetite 
ü ü     
Bioimpedance Analysis (San Lazaro site) (ü) (ü) (ü) (ü) (ü) (ü) 
Blood (5 ml) for Quantiferon-Gold Plus supernatant aliquot 
archived for Luminex Cytokine Assay (N=250 subset) 
(ü)      
Random Plasma Glucose  ü  ü ü ü ü 
HbA1c  (for all patients) ü  ü ü ü ü 
Cross-sectional assessment of Fasting blood glucose and insulin 3 (ü)  (ü) (ü) (ü) (ü) 
Oral Glucose Tolerance Test (if Hba1C ≥5.7% to < 6.5%) ü      
TX history, diabetes co-morbidities in DM & pre-DM cases ü  (ü) (ü) (ü) (ü) 
Household contacts 
 Anthropometry, blood pressure and haemoglobin  ü  ü ü ü ü 
Assessment Time points 
 
End-IP Mid-CP End-CP 
Total patient costs – WHO patient costing tool  ü ü ü ü 
Hemoglobin (finger prick) ü ü ü ü 
Household food security ü ü ü ü 
WHO Quality of Life questionnaire  ü ü ü ü 
Depression, stigma, SFS, Self-esteem, reported side effect of 
medication  
ü ü ü ü 
1 Included time points for DR-TB patients; 2 please see text below regarding potential chest X ray collection; 3 Cross-sectional 
study, with 1 measurement per patient with equal numbers at the different time points.   
IP = intensive phase of treatment; CP=continuation phase of treatment (ü) indicates conducted in subset of participants 
 
Table 3B Summary of data and sample collection in patients post-treatment 














Completion   
Chest x-ray  ü    ü 
Anthropometry [BMI, MUAC, waist:hip ratio]; 
grip strength, blood pressure, reported appetite 
clinical history 
ü ü ü  ü 
Bioimpedance Analysis (San Lazaro site) (ü) (ü) (ü)  (ü) 
HbA1c  (for all patients) ü ü ü  ü 
Fasting blood glucose and insulin (subset tbd) ü  ü  ü 
TX history, diabetes co-morbidities in DM & pre-
DM cases 
(ü)     
Lung spirometry and 6 minute walk test  ü  ü  ü 
St Georges respiratory Questionnaire  ü  ü  ü 
Active TB screening at clinic visit or by telephone  ü ü ü ü 
Sheehan Disability scale  ü ü ü  ü 
Health related behaviors ü ü ü  ü 
Symptom history and health seeking behavior ü ü ü ü ü 
Hemoglobin (finger prick) ü ü ü  ü 
Household food security ü ü ü  ü 
WHO Quality of Life questionnaire  ü ü ü  ü 
Depression, stigma, SFS,  ü ü ü  ü 
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3.10.2. TB diagnostics:  
● TB classification, TB diagnosis (clinical, bacteriological, direct sputum smear microscopy 
(DSSM) including grade, drug resistance (GeneXpert/line probe assays (Hain test), 
DSSM, sputum culture – as available), drug regimen and any changes to drug regimen will 
be obtained from clinical records and patient questionnaires. 
● A study sputum sample will be collected for all patients at enrolment to be archived for 
potential future culture and preservation of isolates for molecular typing and further drug 
sensitivity testing. Samples will be archived at -80 degrees C for up to 10 years after the 
end of the study and linked to the anonymised dataset. The study informed consent 
includes consent for archiving and further testing of these samples for the purpose of TB-
related diagnostics for ethically approved research, but no further informed consent from 
the study participants will be sought. *A funding decision is pending for a research 
proposal to support the continuation and expansion of this cohort to include follow-up for 
risk of recurrent TB – and to investigate the role of re-infection compared to treatment 
failure in recurrent cases. Therefore, this archive will maximise the number of potential 
isolates for comparison between recurrent and previous infection.  
● Study specific chest x-ray at baseline may be collected depending on availability and 
quality of programmatic films. Degree of cavitation will be assessed as a potential 
predictor of disease severity and poor outcome. Additional CXRs will be obtained at end 
of treatment and 24 months post-treatment for those agreeing to participate in the post-
treatment follow-up.  
● WHO symptom screening will be conducted 6 monthly during the post-treatment follow-
up and any found to be positive will be referred for further screening through the usual 
processes (expected to be GeneXpert MTM/Rif testing). In addition Study specific CXRs 
will be conducted at 24 months and will be assessed for findings suggestive of new TB 
disease, and any such cases referred for further testing as above.   
3.10.3. Nutritional status and food security:  
● Weight, blood pressure, MUAC and grip strength (Jamar Dynamometer, grip strength in 
kg) and reported appetite in all patients all visits, height (baseline only) and at 6, 12 and 24 
months post-treatment. Reported previous weight loss at baseline.  
● Hemoglobin (Hemocue 301) point of care test, all patients at baseline, end of intensive 
treatment phase, end of treatment at month 6/9-12 and 6, 12 and 24 months post-treatment. 
● Bioimpedance analysis (BIA) measurement, all patients in San Lazaro Hospital at baseline, 
monthly follow-up, and end of treatment at month 6/9-12 and 6, 12 and 24 months post-
treatment. 
● Household food security (using Adapted U.S. Household Food Security Survey Module 
(US HFSSM)), all TB patients at baseline, end of treatment at month 6/9-12 and 6, 12 & 
24 months post-treatment. 
● Nutritional status for household contact of enrolled index case, approximately 50% of all 
enrolled patients at enrolment.  
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3.10.4. Immune functions:  
● 250 TB patients with microbiologically confirmed TB (DR or DS) will be selected to have 
a 5ml venous blood collection for whole blood stimulation using QuantiFERON-TB Gold 
Plus (QFT). Plasma from 1ml of blood (if available after aliquoting 4 mls of whole blood 
for the QFT) will be frozen and archived for future possible TB-related research. QFT 
supernatants will be frozen and stored for later analysis for multiple cytokines using 
Luminex. Based on previous data we expect that at least 35% of patients with DS TB will be 
bacteriologically confirmed. Thus, enrolling a total of 800 patients and 500-600 with DS TB 
should yield at least 175 DS TB patients eligible for the immune responses assessment, whilst 
all of the DR-TB patients would be eligible. We will aim for 125 of each. 
3.10.5. Diabetes and glycaemic control:  
● Random plasma glucose, POC and HbA1C (Unilab, Trinity POC),  on finger prick 
samples, all patients at baseline and 3 monthly until end of  treatment followed by 6 months 
and 12/24 months post treatment.  
● Oral glucose tolerance test (OGTT) requiring a venous blood sample, patients whose 
HbA1c is ≥5.7% to < 6.5% at baseline or in those with severe anemia (<8g/dL) in whom 
HbA1c measurements may be affected and at very low levels of haemoglobin 
(approx.<6/7g/dL) will not result in an HbA1c reading . Venous fasting blood sugar before 
the glucose load and blood sugar 2 hr after the glucose load (mg/dL) will be used to define 
diabetes (>=126 / >200), pre-diabetes (100-125 / 140- 199) and normal (<100 / <140 ).   
● Information on therapy/management and glycaemic control for diabetic patients  will 
be obtained from clinical records, patient interviews and 3-monthly HbA1C (months 3, 
6 and 9 and 12).  
● Fasting blood glucose and insulin measured in all patients at one time point in a cross-
sectional designed to achieve approximately equal numbers of assessments at baseline, 
end of IP, mid CP and end of CP5.  Further sub-set sampling during post-treatment will 
be determined based on the previous results.  Approximately 1 ml of fasting blood will 
be archived for future possible metabolomics/TB research 
3.10.6. Patient Cost: 
● By interview to patients using adapted electronic version of the WHO catastrophic cost 
tool deployed on ODK platform.  
● Patient costs consist of direct medical cost (e.g. consultation cost, drug cost, diagnostic 
cost before starting treatment, hospitalization and follow-up costs, direct non-medical 
cost (e.g. travel cost, food cost, accommodation cost, opportunity costs of visits 
associated with picking up drugs/consultations) and indirect non-medical cost (e.g. 
opportunity cost by income and asset loss). 
● Information on coping strategies will be obtained from questionnaire about how to 
finance patient costs (e.g. regular income, selling asset, or borrowing money). 
                                               
5 The selected time point for each patients FBS/Insulin will replace the nearest 3 month HbA1c assessment, so 
that RPG/HbA1c, FBS and insulin are all measured at the same single time point for each patient.    
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3.10.7. Co-factors  
● HIV testing at enrolment will be conducted as per guidelines and will require additional 
consent. 
3.10.8. Adherence and its risk factors 
• Adherence to ATT will be assessed by self-report at monthly follow-up visits. In 
addition, electronic pill boxes (Wisepill evriMED500, as referred to in the WHO 
Medication adherence handbook (WHO/HTM/TB/2017.30	) 
(https://www.wisepill.com/evrimed)  will be used in newly enrolled patients after the  
protocol amendment is approved. The evriMED500 registers every time the box is 
opened and the data stored on a disk within. Data is extracted via USB. Battery life is 
up to 2 years. The reminder alarms and light will not be enabled, so as to have 
minimal effect on patient drug taking behavior, but simply provide a means of 
measuring adherence through the proxy of box opening. Local approval from NTP 
coordinators will be obtained for their use and we will coordinate with participating 
health centre staff on their use. We will collect the data from the boxes at  the study 
clinic visits (end of IP, mid CP and end of treatment).  
● Standardized self-reported questionnaires will used to measure depression by using The 
Hospital and Anxiety Depression scale (HADS) , social & family support by using 
Multidimensional scale of perceived social support (MSPSS), stigma using Berger 
scale of stigma and self-esteem using Rosenberg Self-esteem Scale (RSES). These will 
be assessed at baseline, end of IP, mid-CP end-CP and at 6, 12 and 24 months post-
treatment.  
3.10.9. Lung function: spirometry and 6 minute walk test  
• St Georges Respiratory Questionnaire (SGRQ) (a validated disease specific tool 
designed to measure impact on overall health, daily life and perceived well-being in 
patients with obstructive airway disease, available in Cebuano and Tagalog) 
(https://www.thoracic.org/members/assemblies/assemblies/srn/questionaires/sgrq.php.
) will be conducted at end of treatment and at 6, 12 and 24 months post-treatment. 
This will be supplemented by the Sheehan Disability scale (5 item) 
http://memorialparkpsychiatry.com/doc/sheehan_disability_scale.pdf) assessed at the 
same time points. 
• Feasibility of the six minute walk test will be investigated at each study site as per the 
updated guidelines of the American Thoracic and European Respiratory Societies  
guidelines [42]  
• Lung spirometry using NDD EasyOn or EasyOn-PC spirometers and single patient 
use spirettes (no risk of cross-contamination) to assess obstructive, restrictive or 
mixed ventilation impairment will be conducted at the end of treatment and 6, 12 and 
24 months post-treatment by trained research study nurses. This will be deferred 
should the subject be found to have TB relapse. Diagnosis of COPD will be based on 
17 
St-ATT V2.0 3rd May 2019 
 
GOLD 2019 criteria [43] while diagnosis of asthma will be based on those of GINA 
2018 [44].   
 
3.11. Immune function assay methodology 
5 ml Lith Hep blood samples will be collected at the health clinics and transported on ice daily 
to hub sites where blood will be aliquoted into the 4 QFT-Plus tubes and incubated at 37°C as 
per the manufacturer’s instructions and within a maximum of 24 hrs after collection.  After 
incubation, tubes will be centrifuged (15 mins, 2000-3000RCF) and the supernatant aliquoted 
into cryotubes and stored at -20˚C until monthly transfer to the central laboratory for longer 
term storage at -80˚C and batch analysis of cytokine responses using a multiplex assay.  
4. Sample size 
 
4.1. Primary objective: association between malnutrition and adverse treatment 
outcome  
Assuming 90% power and 5% significance, a sample size of 800 patients will allow a detectable 
odds ratio of at least 2.1 if 25-30% of patients are malnourished and approximately 10-20% of 
patients have adverse treatment outcomes. 
4.2. Primary objective: Association between diabetes and adverse treatment 
outcome 
Assuming 90% power, and 5% significance a sample size of 800 patients will allow a detectable 
odds ratio of at least 2.8 if 10-12% of patients have diabetes and approximately 10-20% of patients 
have adverse treatment outcomes.  
4.3. Secondary objective: malnutrition on cell mediated immune responses  
Assuming 90% power and 5% significance and 30% malnutrition at enrolment a sample size 
of 250 (limited to those with bacteriological confirmation) should allow a difference in mean IFN-
γ concentrations (in response to TB-specific antigen stimulation) equivalent to half a standard 
deviation to be detected between BMI groups <17 vs ≥17kg/m2. This is based on estimates using 
previous IFN-γ data from 25 TB patients at San Lazaro Hospital who had not yet started ATT with 
BMI<17 compared to those with BMI >17 tested using with QFTGold (Appendix 1). No suitable 
data was available for other cytokine responses. 
4.4. Secondary objective: prevalence of post-treatment adverse health 
outcomes 
Assuming 600 of the original 800 participants can be traced at 24 months post-treatment, this 
sample size will provide at least 90% power to estimate the prevalence of adverse outcome, 
e.g. proportion with  a total score >=8 on SGRQ of predicted value within ±4%, if the true 
prevalence is 20% allowing for a design effect of 1.5 and with increased relative precision at 
higher prevalence of the selected outcome or with a lower design effect.   
 
4.5. Sampling Strategy 
800 study participants >18 years newly starting anti-TB treatment during the study enrolment 
period at selected TB DOTS clinics from within Metro Manila, Negros Occidental and Cebu 
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will be approached for enrolment. The final selection of TB-DOTS centres will be based on 
achieving 200-300 DR-TB patients out of the total 800, and balanced between urban and semi-
urban/rural sites.  Logistical considerations including the number of Barangays being served 
by each Health Centre and distances from regional hub sites for the processing of blood samples 
(patient sub-set for immune responses) will also be taken into account. Currently sites will 
include those in which we have already worked including San Lazaro Hospital and San Nicolas 
Health Centre in Manila and Bago City and Valladolid Health Centres in Negros Occidental.  
>> updated 2nd May 2019 >> Please see updated list of study sites in section 3.6.  
5. Data collection 
Trained research nurses will be based in each study site to recruit newly diagnosed TB patients 
into the cohort study. For the DS TB patients in the more rural sites in Negros and Cebu, where 
patients may reside far from the Health Centre TB DOTS clinic, after registration, routine care 
is transferred from the managing health centre TB DOTs clinic to Barangay health stations and 
directly observed treatment is done by the Barangay health workers and designated treatment 
partners. Thus, the monthly follow-up visits will be conducted by our research nurses at either 
the Barangay health stations or at the managing TB-DOTS health centre as per the patients’ 
routine treatment requirements.  For the patient cost assessment, those that agree to participate 
will have home visits scheduled for the patient cost interview to be conducted by a trained 
research nurse. Data for the post-treatment follow-up will be collected by the research study 
nurses at the health centres. WHO symptom screening at 18 months post-treatment will be done 
by telephone and a clinic visit facilitated  if they are screen positive, to receive further testing 
for active TB disease as per local procedures.  
6. Data Management and Security 
Research nurses will directly enter data into tablets using the Open Data Kit (ODK) platform 
(Open source) supported by the London School of Hygiene and Tropical Medicine. Tablets 
will be password secured and stored in a locked cabinet in a locked room when not in use. No 
patient data will remain on the tablet hard drive once data entry has been confirmed in real 
time. Paper-based data collection will be available if significant technical problems occur. 
Encrypted data from the tablets will be automatically uploaded to a secure and backed up 
server. Data quality will be continuously monitored by Philippines based co-investigator, and 
can be reviewed remotely by approved DOTS administrative and ethical board members 
subject to setting up access account. Data may only be reviewed but not altered.  
7. Data Analysis 
Data analysis will be conducted in Stata 14.1 (StatCorp LP). 
The prevalence of each outcome will be presented as a percentage with corresponding 95% 
confidence intervals, overall and by region. Descriptive data summaries will correspond to data 
type; mean (SD) and median (range) for continuous and discrete data, raw numbers and 
percentages for binary and categorical variables. 
The strength of evidence for associations between exposure variables of interest will be 
investigated using tests appropriate to data type; chi-squared tests (or Fisher’s exact test as 
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appropriate) for association between categorical variables, spearman’s correlation test, t-test, 
ANOVA or non-parametric tests for continuous data and categorical data associations. 
Univariable analyses to quantify associations between exposures and the primary outcome of 
adverse treatment outcome, including death, treatment failure or default will be explored using 
logistic regression. A priori adjustments will be made, in the final model for each exposure 
(malnutrition and diabetes), for age and sex; These are known to be associated with TB, 
diabetes and lifestyle risk factors for each outcome. Adjustment will also account for any 
chance variability in age and sex distribution by study site. Final multivariable models for each 
exposure will be built using a step-wise strategy with inclusion and exclusion criteria of 0.1 
(10% significance). 
8. Ethics 
8.1. Informed consent 
All patients will be consented in the local language (Tagalog, Hilagaynon6, or Cebuano) prior 
to inclusion in the study. Study information will be provided in written form and translated 
from English into Filipino, Hilagaynon and Cebuano. Consent forms will be back-translated to 
ensure accuracy of content. 
Research nurses will complete the informed consent in a quiet and private location to ensure 
patients have free and voluntary consent uninfluenced by health centre staff. Privacy will be 
promoted to the highest level possible in the facilities where consent is obtained but at 
minimum it will be asked that the regular staff of the health centre are not present at time of 
consent to avoid coercion into the study. It will be stressed throughout the consent process that 
the research is voluntary and will not impact the care they receive from the clinic. 
The patient may choose not to participate in this study and may refuse to participate or 
withdraw from the study at any time without penalty or loss of benefits to which they would 
otherwise be entitled. They do not have to explain why they do not wish to participate or why 
they want to withdraw. Refusing to take part in this study will not alter the treatment they are 
receiving in any way. 
 
Optional HIV screening will be consented through a separate informed consent process, 
following the DOH protocols for HIV Counselling and Testing (HCT) – with consent being 
obtained by an individual who has received the appropriate DOH training.  
 
For participants who are already enrolled in St-ATT, additional consent will be sought to 
participate in the post-treatment follow-up at the end of continuation phase clinic visit. For 
patients newly enrolling after the post-treatment follow-up has started, informed consent for 
both follow-up periods will be sought. For patients who have already completed ATT before 
post-treatment-follow up has started, they will be contacted by phone and invited to participate, 
starting with the first 6 month follow-up visit, unless the 6 month post-treatment follow-up 
period has already passed.    
 
                                               
6 Hilagaynon – is the correct term, corrected from Illongo before V2.0.  
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8.2. Patient confidentiality 
All patient data will be anonymized using unique patient identifier numbers. The database will 
be stored as an encrypted file, with end-to-end encryption transfer of data. Only approved 
primary and co-investigators will have full access to modify dataset, all other team members 
may have access to view but not modify data. Only anonymized data will be used in the final 
analysis dataset and be made available after completion of the study and analysis of the main 
objectives on request by other researchers.   
 
8.3. Referrals 
Patients who screen positive for possible diabetes (HbA1C >=6.5%) will be referred to the 
doctor at the local health centre for further diagnostic tests and follow-up care, and therefore 
the MDs in the LHCs will be involved and government resources maximized (ie, medications, 
counselling). This will be implemented through letters from the study investigators to the LHC 
MDs listing participant lab results and indicating those that require further management.  This 
study also has physicians as study co-investigators/team members (Dr Juan Solon, Dr Mary 
Christine Castro), and therefore the LHC MDs also can involve them to decide further 
managements for patients.  Study participants who agree to HIV screening and are found to be 
reactive will need to have a serum sample submitted to an approved lab for confirmatory 
testing. Individuals will have been pre-informed during their HCT counselling about the steps 
that will occur if their result on the rapid screening test is reactive. Normal DOH referral 
procedures will be followed and the appropriate individuals notified. Patients are moderately 
or severely anemic (hemoglobin <11.0 g/dL) are referred back to their respective health 
facilities.  Patients who are found during the post-treatment follow-up to meet the diagnostic 
criteria (or other criteria as advised by local specialists) for chronic obstructive pulmonary 
disease (COPD) or asthma will be reviewed by the study specialist collaborators who will refer  
to local facilities as appropriate with copies of the spirometry test and any other relevant data.  
 
8.4. Subject remuneration 
Based on local advice and procedures and our previous experience we are proposing to provide 
small remunerations at each study visit in the form of phone credit (from any of the main 
networks). In rare circumstances in which the participant does not have access to a mobile 
phone, a cash equivalent will be provided. 
For TB patients: At the baseline visit they will receive the equivalent of PHP 150 and then 
PHP 50 at each monthly follow-up visit completed. If they agree to participate in the TB patient 
cost study they will receive an additional PHP 250 for each home visit (4 times in total). TB 
patients who agree to provide a fasting blood sample at a selected clinic visit during treatment 
or after TB treatment will be provided with breakfast at the clinic and an additional PHP 50.  
Participation in clinic visits at 6, 12 and 24 months post-treatment will be compensated the 
equivalent of PHP 250 at each visit.   
For HHCs: At the baseline visit they will receive the equivalent of PHP 250 and then PHP 150 
at each 3-monthly follow-up visit completed 
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9. Proposed Budget and Funds 
The total budget for this project is 30,000,000 JPY (approx. PHP 14.05 million) supported by 
research funding from Grants-in-aid for Scientific Research (Kakenhi) awarded to Professor 
Sharon Cox at Nagasaki University and Nagasaki University research funding.  
 
10. Investigators 
Primary Investigator  
- Professor Sharon Cox (Nagasaki University School of Tropical Medicine & Global 
Heath, Japan & The London School of Hygiene & Tropical Medicine, UK) 
 
Co-investigators  
- Dr Juan Solon (Nutrition Centre Philippines) 
- Dr Celine Garfin (National TB Programme, Philippines) 
- Professor Koya Ariyoshi (Nagasaki University School of Tropical Medicine & Global 
Heath, Japan) 
- Mary Christine R. Castro (Nutrition Center of the Philippines)   
Study statistician & Co-investigator 
- Dr Tansy Edwards (The London School of Hygiene & Tropical Medicine, UK) 
Collaborators 
- Dr. Naomi R. Saludar (SLH) – DOTS program 
- Dr. Nelson Dela Fuente (Valladolid MHO) 
- Dr. Georgina Hufanda (Bago City MHO) 
- Dr. Emil Arleen Morales (San Nicholas H/C MHO 
- Dr Elizabeth Hollero (Dept of Radiology, Pablo O. Torres Memorial Hospital, Bacolod, 
Negros Occidental.  
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Appendix 1.  Sample size calculation for immune function 
analysis using QuantiFERON-TB Gold Plus 
Sample sizes were based on calculations using data as shown in the table below: 
 
Table A1: Geometric mean and geometric standard deviation calculated using previous 
IFN-γ data from TB inpatients and outpatients in SLH (Unpublished data, Ariyoshi et al, 
Nagasaki University)  
 Geometric mean Geometric standard 
deviation 
Not on ATT (N=25) 4.81 1.87 
BMI<17.0 kg/m2 (N=14) 4.24 1.72 
BMI≥17.0 kg/m2 (N=10) 5.06 1.82 
 
 
Figure 1: Power provided by different sample sizes to detect a difference of 1 or 0.5 of a 
SD for IFN-γ responses in response to QFTGold antigen stimulation.  
 
A sample size of 250 with a ratio of BMI<17.0 kg/m2 vs BMI≥17.0 kg/m2 (1:3) is estimated to 
provide 90% power to detect a difference in the geometric mean IFN-γ equivalent to half a 
geometric standard deviation. 
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Appendix 2. Document submission and modification history  




for change  
Changes (in status or in material content) 
D6.0_180131 31st Jan 18 Submitted TMGH Approved March 1st 2018.  
D6.1_180206 6th Feb 18  Minor Updates, clarifications and 
corrections based on  feedback from WPRO 
reviewer and in preparation for LSHTM 
submission.  
Limited to pulmonary TB cases.  
Added cut-offs for OGTT to confirm pre-
diabetes/diabetes/normal in those with 
intermediate HbA1C. 
Changed terminology  
D6.2_180207 7th Feb 2018  Changed terminology to DS instead of non-
DR TB 
Changed Ref 28.  
D6.2_180207 12th Feb 2018 Submitted LSHTM 
LEO 
 
D6.3_180312 12th Mar 2018 Submitted AEI Added GANTT chart and dummy tables. 
D6.4_180418 20th April 2018 Resubmitted AEI Minor additions from AEI comments [minor 
changes to IC sheets from AEI & LSHTM] 
D6.4_180418 23rd April 2018 Resubmitted 
LSHTM 
Minor additions from AEI comments [minor 
changes to IC sheets from AEI & LSHTM] 
V1.0_180615 15th June Approved version  Edited to include details of all obtained 
approvals and change to a version. This may 
be further edited for additions in details and 
clarity. Before data collection starts the final 
version “in use” should have APPROVED 
watermark added and that version included 
to the  study document control log. All 
minor amendments to be added as V1.X and 
recorded here. 
D2.2_20180626 28th June Submitted San 
Lazaro Hospital site 
specific protocol 
Version  based on V1.0_180615 but with 
additional SLH specific requirements 
/budget section, required appendices  and 
description of linked activities for separate 
but related immuno sub-study with its own 
submitted protocol.  
V1.1_180801 1st August  Correction to an error in units in random 
plasma glucose and clarification of 
inconsistency in text about criteria for 
HbA1C testing – text in red.  
V1.2_180920 
(equivalent to AEI 
D6.5_180920) 
20th Sep Amendment 
submitted to AEI 
Addition of assessments of Depression, 
using the Hospital Anxiety Depression Scale 
(HADS) tool, Social & family support using 
Multidimensional scale of perceived social  
support (MSPSS), Stigma using Berger scale 
of stigma  & self-esteem using Rosenberg 
Self-esteem Scale (RSES) at baseline, end of 
intensive phase, mid continuation and end 
of continuation phase. Additional text for 
background and justification section 2.6 
added. Additional secondary objective, 
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section 3.3. More references added. Table 3 
modified to show extra assessments and 
time points, plus in the Data collection 
appendices.  
Additional Co-investigator added. Dr 
Elizabeth Hollero, Riverside Hospital, 
Philippines.   
D2.2_0180626 2nd October  Approval from SLH NB. SLH specific informed consent 
documents approved [SLH_V5.4 SLH_HHC 
V3.2, SLH_HIV_1.1] All dated Sep 27 2018.  
Added site specific CBC to those 
participating in immune-sub study.  
SLH_V1.0_20181129 29th November SLH Approved 
Version  
SLH specific Approved version in use [Added 
specific CBC instead of Hemocue  to those 
participating in immune-sub study]. 
V1.2_180920 
 
5th October  Submitted to Pablo 
O. Torres Memorial 
Hospital as a new 
site for site-specific 
ethical approval 
 
V1.2.1_181018  18th Oct Amendment 
submitted to 
LSHTM 
Minor formatting changes, typos. 
Correction, removing  “self administered” 
from the  questionnaires for depression … 
[HADS, MPSS & RSES]”. These will be 
administered by the research nurse as for 
the other questionnaires. 
V1.2.2_181207 7th December RE-Submitted to 
Pablo O Torres 
Memorial Hospital  
[Riverside]  
Edits to the list of co-investigators and 
collaborators – Dr Elizabeth Hollero (Dr. 
Pablo O.  Torre Memorial Hospital 
[Riverside]) changed from Co-investigator to 
collaborator. 
Dr Mary Castro, Nutrition Center Philippines 
added as a Co-investigator 
V2.0_190503    
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Appendix 3. Questionnaires  
For our data collection we will be using the ODK tablet based data collection platform. All 
questions will be built into an ODK readable form and uploaded to the server for download 
onto individual tablets. Data to be collected is summarised below 
a. Questionnaire: Baseline at start of treatment 
• Demographic Factors 
o Date of Questionnaire Completion (dd/mm/yyyy) 
o DOTS Center participant recruited from (where registered) 
o Location of interview (Barangay Health Station name/ home/local health centre) 
o Study ID 
o DOB  (dd/mm/yyyy) 
o Sex (M/F) 
o Phone number  
o Area of residence: Barangay level 
o Educational Level (none, primary, secondary, tertiary, vocational) 
o SLH social service categorization (A, B, C1, C2, C3, D) 
o Occupation 
o Cigarette smoker (Y/N/Ex-smoker) and burden (# of pack-years) 
• Clinical Management 
o Basis of current TB diagnosis and diagnostic results (smear+/- & grade), (culture+/-;), Gene 
Xpert, Clinical diagnosis  - and dates of tests/diagnosis 
o Symptom history (cough, fever, night sweats, unintentional weight loss, haemoptysis, 
other ) including date of start of symptoms and date of diagnosis.   
o DR-TB or DS-TB  
o Previous TB treatment history – relapse; treatment after loss to follow up [TALF]; 
treatment after failure or previous treatment outcome unknown [PTOU].  
o Anti-TB medication regime and indication including date of initiation (dd/mm/yyyy) and 
doses taken since initiation 
§  Which anti-MTB medications (Checklist) 
• First line; Isoniazid, Rifampin, Rifapentine, Rifabutin, Ethambutol, 
Pyrazinamide 
• Second line; Cycloserine, Ethionamide, Levofloxacin, 
Moxifloxacin/gatifloxacin, p-Amino-salicylic acid, Amikacin/kanamycin, 
capreomycin 
o Known diabetes (date of diagnosis–year) and its management 
(Metformin/Gliclazide/other medication use and dietary modifications)  
o Co-morbidities (HIV, chronic kidney disease, chronic obstructive pulmonary disease, 
hypertension, other)  
o Chest x-ray results 
• Nutritional Status 
§ Height (metres) 
§ Weight (kg) 
§ BMI (kg/m2) 
§ Grip strength (kg; Jamar Hydraulic Hand Dynamometer Lafayette Instruments, 
USA) 
§ Mid-upper arm circumference (MUAC) in cm 
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§ Waist -Hip ratio 
§ Unplanned weight loss in the last 3-6 months  
§ Current appetite 
• Clinical investigations 
o Blood pressure  
o Random plasma glucose (RPG) – finger prick sample. 
o HbA1c - diabetes point of care test using fingerprick blood sample if RPG ≥6.1mmol/L (110 
mg/dL)  
o Oral glucose tolerance test if HbA1C>5.7 &<6.5% 
o Haemoglobin – anaemia point of care test using fingerprick blood sample 
o HIV rapid diagnostic test (if consent given) – point of care test using finger prick sample  
• Household food security (using Adapted U.S. Household Food Security Survey Module (US 
HFSSM))18  : 
  In the last 12 months: 
§ 1. Were you worried that your food would run out before you had money to buy more? 
A) Yes             B) No – Go to question 2  
§ 1a. How often did this occur?  
1) Often      2) Sometimes           3) Rarely 
§ 2. The food you had didn’t last, and you did not have enough money to buy more? 
A) Yes             B) No 
§ 3. Did you have to eat the same foods daily because you did not have money to buy other 
foods? 
A) Yes             B) No  
§ 4. Have you or any other adult in your household cut the size of your meals because you 
did not have enough money to buy food?  
A) Yes             B) No 
§ 5. Did you skip some of your daily meals because you did not have enough money for 
food?  
A) Yes             B) No 
§ 6. Did you ever eat less than you felt you should because you did not have enough money 
to buy food?  
A) Yes             B) No 
§ 7. Were you ever hungry and did not eat because you did not have money to buy enough 
food?  
A) Yes             B) No 
§ 8.  Did you lose weight because you did not have enough money to buy food?  
A) Yes             B) No 
§ 9. Did you or another adult in your household ever not eat for a whole day because you 
did not have enough money to buy food? 
A) Yes             B) No  
• Quality of life using the WHO-BREF WHOQOL  [Questions will be converted into ODK compatible 
format] 
• Total patient costs, adapted WHO costing tool (Tool to estimate Patients’ costs, USAID). At 
baseline questions will concern the costs associated with health seeking behaviour and diagnosis 
from the onset of symptoms – specific to TB and to DM - If applicable. Repetitions of the 
questionnaire will be cover the relevant periods, e.g. from start of treatment to completion of the 
intensive phase and be specific to TB and DM. Questions, developed as a result of our previous 
pilot will also ask about health seeking behaviour, and costs associated with other co-morbidities 
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including managing drug side-effects, malnutrition, digestion and general wellbeing – including 
purchase of special foods, supplements or herbal/other remedies 
o Direct Medical Costs 
§ Outpatient Service Cost 
§ Registration Cost 
§ Diagnosis/Laboratory Cost 
§ Dispensing Cost 
§ Drug Cost 
§ Supplements/herbal remedies Cost 
§ Hospitalization Cost 
§ Other Service Cost  
§ Expenditure at other facilities 
o Direct Non-Medical Costs 
§ Transportation Cost 
§ Accommodation Cost 
§ Special Meal/Drink Cost 
§ Informal/Traditional Care Cost at home & outside of home 
§ Cost of Facilities/Equipment at home 
§ Number of visits to facilities 
§ Time Loss for facility visit for Patient 
§ Time Loss for facility visit for Accompanies 
§ Payment to paid caregivers 
o Indirect Costs 
§ Current and previous income to estimate income Loss due to Work Absence of 
Patient and household member 
§ Cost of Permanent Disability 
§ Payment of Interest due to Loan 
o Coping Strategies 
§ Using cash/mobilizing savings 
§ Sales of assets  
§ Taking loans  
§ Support from relatives or community  
§ Income Diversification by Using Leisure Time 
§ Working as a Wage-Labor 
§ Drop out of child’s schooling 
• Risk factors related to adherence  
o Depression using Hospital Anxiety Depression Scale (HADS) 
o Social & family support by using Multidimensional scale of perceived social   support 
(MSPSS) 
o Stigma using Berger scale of stigma  
o Self-esteem using Rosenberg Self-esteem Scale (RSES). 
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b. Questionnaire: Monthly (All participants)  
• Demographic Factors 
o Date of Questionnaire Completion (dd/mm/yyyy) 
o DOTS Center where registered – check if changed 
o Location of interview (Barangay Health Station name/ home/local health centre) 
o Study ID 
o Phone number – check if changed 
o Area of residence: Barangay level – check if changed 
o Cigarette smoker (Y/N/Ex-smoker) – check if changed 
• Nutritional Status & Blood pressure 
o Weight (kg) 
o BMI (kg/m2) 
o Mid-upper arm circumference (MUAC) in cm 
o Grip strength (sub-set) 
o Body composition by bio-impedance analysis (San Lazaro site only) 
o Blood pressure  
o Unplanned weight loss in the last month 
o Current appetite 
• TB Treatment adherence (from patient treatment record and patient interview (last seven days) 
o Check if change in regimen – and reasons why 
o Adherence (last 7 days) – and reasons why if non-adherent 
• DM treatment and monitoring (if applicable) 
o Check if any change in treatment – and reasons why 
o Adherence – if applicable (last 7 days) and reasons why if non-adherent  
o Blood glucose monitoring in the last month -  Y/N, last result if available.  
• Occurrence of TB side-effects (extraction from routine records and by patient interview, last 7 days) 
c. Questionnaire: End of intensive treatment phase, mid continuation and 
end of continuation – to include and replace usual monthly  data collection 
(All participants) 
• Clinical investigations 
o Haemoglobin – anaemia point of care test using fingerprick blood sample 
• Household food security (using Adapted U.S. Household Food Security Survey Module (US HFSSM))18   
- as described at baseline, but adapted to ask about the relevant period since the last assessment: 
• Quality of life using WHO BREF tool 
(https://www.who.int/substance_abuse/research_tools/en/english_whoqol.pdf)   [Questions will be 
converted into ODK compatible format 
• Total patient costs, adapted WHO costing tool – as described at baseline  
• Risk factors related to adherence  
o Depression using Hospital Anxiety Depression Scale (HADS)  
o Social & family support by using Multidimensional scale of perceived social   support (MSPSS) 
o Stigma using Berger scale of stigma  
o Self-esteem using Rosenberg Self-esteem Scale (RSES). 
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d. Questionnaire: Household contacts: Baseline  
• Demographic Factors 
o Date of Questionnaire Completion (dd/mm/yyyy) 
o Location of interview (Barangay Health Station name/ home/local health centre) 
o Study ID and name/ID of enrolled TB contact and relationship to the TB patient 
o Duration of residence in same household as TB patient 
o DOB  (dd/mm/yyyy) 
o Sex (M/F) 
o Phone number  
o Area of residence: Barangay level 
o Educational Level (none, primary, secondary, tertiary, vocational) 
o SLH social service categorization (A, B, C1, C2, C3, D) 
o Occupation 
o Cigarette smoker (Y/N/Ex-smoker) 
• TB screening  tests done: CXR   Y/N, smear  Y/N , GeneXpert Y/N and dates/results of tests 
• General health status and co-morbidities 
o Any previously diagnosed conditions – including diabetes and hypertension 
o Any medications – prescribed, being taken.  
• Clinical investigations 
o Haemoglobin – anaemia point of care test using fingerprick blood sample 
• Nutritional Status & Blood pressure 
o Weight (kg) 
o Height 
o BMI (kg/m2) 
o Mid-upper arm circumference (MUAC) in cm 
o Grip strength  
o Body composition by bio-impedance analysis (San Lazaro site only) 
o Blood pressure  
o Unplanned weight loss in the last month 
o Current appetite 
e. Questionnaire: Household contacts: Follow-up at 3, 6, 9* & 12* months (* 
9/12 months if HHC of DR-TB patient) 
• Demographic Factors 
o Date of Questionnaire Completion (dd/mm/yyyy) 
o Location of interview (Barangay Health Station name/ home/local health centre) 
o Check if still resident in same household as enrolled TB patient 
o Phone number – check if changed  
• Clinical investigations 
o Haemoglobin – anaemia point of care test using fingerprick blood sample 
• Nutritional Status & Blood pressure 
o Weight (kg) 
o BMI (kg/m2) 
o Mid-upper arm circumference (MUAC) in cm 
o Grip strength  
o Body composition by bio-impedance analysis (San Lazaro site only) 
o Blood pressure  
o Unplanned weight loss in the last month 
o Current appetite 
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f. End of Treatment and Post-treatment Data Collection at 6, 12 (18) and 24 
months post treatment 
• Chest X-Ray (end of Treatment, 24M after treatment completion) -As described at baseline 
• Anthropometry (end of treatment, 6M, 12M, and 24M after treatment completion) – As described at 
baseline 
• Haemoglobin (finger prick) (end of treatment, 6M, 12M, and 24M after treatment completion)  
• Bioimpedence Analysis (end of treatment, 6M, 12M, and 24M after treatment completion for SLH 
patients) – As described at baseline 
• HbA1c (end of treatment, 6M, 12M, and 24M after treatment completion) – As described at baseline  
• Diabetes/other co-morbidities medical treatment. (end of treatment, 6M, 12M, and 24M after 
treatment completion) – As described at baseline  
• Active TB screening at clinic visit or by telephone (6M, 12M, 18M and 24M after treatment 
completion)- WHO symptom screening  - Follow local NTP processes (if your symptom screening is 
positive, we call patients in)   
• Lung spirometry and 6 minute walk test (end of treatment, 12M and 24M after treatment 
completion)  
o Forced Vital Capacity (FVC)  
o FEV1 
o FEV1/FVC ratio  
o VC 
• Modified Medical Research Council Dyspnea Score,  (MMRC) (end of treatment, 6M 12M and 24M 
after treatment completion)  
• St Georges Respiratory Questionnaire (end of treatment, 6M 12M and 24M after treatment 
completion)  
o 50-item questionnaire including three domains: symptoms, activity and impact to calculate a 
total score to measure health status in patients with respiratory disease. 
• Sheehan Disability scale (End of treatment, 6M, 12M and 24M after treatment completion) 
o 5-item self-report tool to assess functional impairment on three domains: work/school, social 
life, and family life 
• Health related behaviours: smoking, alcohol, drug-use, changes in behaviour post-treatment (End of 
treatment, 6M, 12M, and 24M after treatment completion)  
• Occupation & Income – changes since completing treatment; 6M, 12M, and 24M after treatment 
completion)  
• Symptom history and health seeking behaviour -changes since completing treatment, 6M, 12M, 18M 
and 24M after treatment completion)  
• Household food security (end of treatment, 6M, 12M, and 24M after treatment completion as 
described at baseline)  
• WHO-BREF Quality of Life Questionnaire (end of treatment, 6M, 12M, and 24M after treatment 
completion as described at baseline)  
Depression, stigma, SFS (End of treatment, 6M, 12M, and 24M after treatment completion as 
described at baseline)  
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Year 2018 2019 2020
Month Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Phase 1: Preparation
Protocol Preparation












Stakeholder Meeting for Study Kick-Off
Research Staff Recruitment
Staff Training
Phase 3: Data Collection
Baseline Data Collection
Treatment Data Collection
Post Treatment Data Collection 
Data Quality Monitoring
Research Manager Site Visits




Analysis for Follow-Up/Treatment Outcome
Analysis for post treatment data
Phase 5: Dissemination
Preliminary Result Dissemination - Baseline
Final Result Dissemination - All
Manuscript and Submission
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Gantt chart (updated)-continued. 
 
Master Timeline
Year 2021 2022 2023
Month Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar
Phase 1: Preparation
Protocol Preparation












Stakeholder Meeting for Study Kick-Off
Research Staff Recruitment
Staff Training
Phase 3: Data Collection
Baseline Data Collection
Treatment Data Collection
Post Treatment Data Collection 
Data Quality Monitoring
Research Manager Site Visits




Analysis for Follow-Up/Treatment Outcome
Analysis for post treatment data
Phase 5: Dissemination
Preliminary Result Dissemination - Baseline
Final Result Dissemination - All
Manuscript and Submission
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Appendix 5 Dummy tables (needed for AEI? Not needed for 
LSHTM/TMGH) 
 
Table 1. Demographic 








value All   
  n=x  (%) n=y (%)   n=x+y (%) 
Sex               
Male               
Female               
Age               
Mean±SD               
Education               
None               
Primary               
Secondary               
Tertiary               
Employment Status               
Employed               
Unemployed               
Marital Status               
Single               
Married               
Widow/Divorced               
Family Size               
≦5               
>5               
Household Income               
Mean±SD               
Under Poverty Line               
Under National Average               
Above National Average               
Urban/Rural               
Metro Manila               
Cebu               
Negros Occidental               
Smoking               
Yes               
No               
Ex-Smoker               
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Table 2. Clinical Characteristics of 








value All   
  n=x  (%) n=y (%)   
n=x+
y (%) 
Diagnosis               
Clinically Diagnosed               
Smear-Positive               
Xpert Positive               
Drug Susceptibility               
DS-TB               
DR-TB               
TB Registration               
New               
Relapse               
Treatment After 
Failure               
TALF               
PTOU               
HIV               
Positive               
Negative               
Unknown               
TB Regimen               
Category I               
Category Ia               
MDR-shorter regimen               
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Table 3. Clinical characteristics of Anthropometry & 
Diabetes by treatment success7         







All   




BMI               
≦17.0               
>17.0               
BMI Mean±SD        
MUAC               
Mean±SD               
Body Fat & Muscle               
Mean±SD (Body Fat)               
Mean±SD (Body Muscle)               
Haemoglobin Level               
Normal               
Mild and moderate               
Severe               
Blood Pressure               
Mean±SD               
Diabetes Diagnosis                
Normal                
Pre-Diabetic                
Diabetic                
Diabetes Treatment               
None               
Mono Therapy               
Dual Therapy or More without 
Insulin               
Dual Therapy or More with Insulin               
Other               
Diabetes 
Complication/Disability               
Yes               
No               
 
Stratification by Urban/rural and DS/DR TB will be investigated
                                               
7 Basic tables only shown for primary outcome. Analysis will likely include multiple level models of time-varying co-variates, 
e.g. multiple measures of nutritional status as a risk factor for the primary outcome of adverse treatment outcome 
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Table 4. Characteristics of Anthropometry & Diabetes in 
HHC compared to TB index cases – analysis adjusting for 
clustering within households, may be stratified by 
urban/rural, DS-DR-TB status, Household income level.          
  HHC TB index case P-value All  
  n=x (%) n=y  (%)  n=x+y (%) 
BMI               
≦17.0               
>17.0               
MUAC               
Mean±SD               
Body Fat & Muscle               
Mean±SD (Body Fat)               
Mean±SD (Body Muscle)               
Haemoglobin Level               
Normal               
Mild or moderate               
severe               
Blood pressure         
Mean±SD        
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Table 5. Total Patient Costs *may be stratified by  DM vs non-DM, urban vs rural and 
association with treatment outcome assessed.    
  DS-TB DR-TB 
P-
value 
  Mean (%) Mean (%)   
Total Patient Cost           
Direct Cost           
Direct Medical Cost           
Outpatient Service Cost           
Diagnosis/Laboratory Cost           
Dispensing Cost           
Drug Cost           
Supplement/Herbal Remedies Cost           
Hospitalization Cost           
Other Service Cost           
Expenditure at Other Facilities           
Direct Non-Medical Cost           
Transportation Cost           
Accommodation Cost           
Special Meal/Drink Cost           
Informal/Traditional Care Cost at home & outside of 
home           
Cost of Facilities/Equipment at home           
Cost of Time Loss to Visit for Patient           
Cost of Time Loss to Visit for Accompanies           
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Indirect Cost           
Indirect Non-Medical Cost           
Income Loss due to Work Absence for Patient           
Income Loss due to Work Absence for Family           
Cost of Permanent Disability           




Table 6. Patient Costs as a Proportion of 
Household Income     
  DS-TB DR-TB P-value 
  Mean (%) Mean (%)   
Monthly 
Household 
Income           
TB 
Diagnosis           
Intensive 
Phase           
Continuatio
n Phase           
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Table 7. Proportion of households with catastrophic costs by DM 






TB total costs P-value 
  # (%) # (%)   
Diabetes 
Diabetic on treatment 
Diabetic not on treatment 
Non diabetic     
  
    
Malnutrition     
  
    




>17.0       
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Table 8. Patient Coping Strategy for TB 
Patient         
  DS-TB DR-TB P-value 
  # (%) # (%)   
Total Number of Patients           
Coping Strategy           
Using cash/mobilizing savings           
sales of assets            
Taking loans            
Support from relatives or community            
Income Diversification by Using Leisure 
Time           
Working as a Wage-Labor           
Drop out of child’s schooling           
 
 
Table 9. prevalence of adherence among TB patients with and without malnutrition and DM  
 
  Adherence  Non-adherence  P-value 
  # (%) # (%)   
Diabetic       
  
  
Non diabetic      
Malnutrition       
  
  




BMI >17.0       
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Table 10. The effect of risk factors on adherence 
 
  Adherence  Non-adherence  P-value 
  # (%) # (%)   
Depression     
Social & family support      
Self-esteem      
Stigma      
 
 
